Alexandria Forbes, Ph.D., is the President and Chief Executive Officer at MeiraGTX Holdings PLC, a clinical-stage gene therapy company focused on developing treatments for a wide range of serious diseases. Dr. Forbes brings a wealth of experience in the biopharmaceutical industry, having held key leadership positions at several prominent organizations. Before joining MeiraGTX, she served as the Chief Business Officer at Spark Therapeutics, where she played a pivotal role in the company's growth and the successful launch of Luxturna, the first FDA-approved gene therapy for an inherited retinal disease. Dr. Forbes' academic credentials are equally impressive. She holds a Ph.D. in molecular biology from the University of Pennsylvania and has published numerous peer-reviewed articles in prestigious scientific journals. Her expertise in gene therapy and her strategic vision have been instrumental in guiding MeiraGTX's research and development efforts. Under her leadership, the company has made significant strides in advancing its pipeline of innovative gene therapies, with several candidates currently in clinical trials. As President and CEO of MeiraGTX, Dr. Forbes is responsible for overseeing the company's overall strategy, operations, and growth. She works closely with the board of directors and the executive team to ensure that MeiraGTX remains at the forefront of the gene therapy field. Her leadership has been crucial in securing partnerships and investments that have enabled the company to expand its research capabilities and bring potentially life-changing treatments to patients worldwide. Dr. Forbes' dedication to advancing medical science and her commitment to improving patient outcomes make her a respected figure in the industry.